Fair Value Calculator Fair Value Calculator
EN DE

CHLOGIST (CHLOGIST) Fair Value & Analysis

IN · Market cap ₹834M

C CHLOGIST CHLOGIST · BSE
Price₹6.56
Fair Value₹3.32
Upside-49.4%
Quality41/100
Watch CHLOGIST for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range ₹1.98 – ₹3.32

Fair value as of: Jul 5, 2026

From 10 valuation models · updated yesterday

Share price −1.4% over the past month.

Price vs Fair Value (12 months)

₹9.71 ₹5.05 Fair Value ₹3.32 Jul 2025 Jul 2026

12‑month range ₹5.05 – ₹9.71 · fair‑value band ₹1.98 – ₹3.32 · the ₹6.56 price screens above the ₹3.32 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

CHLOGIST (CHLOGIST) currently trades at ₹6.56, while our model-based Fair Value estimate is ₹3.32 — implying the stock looks roughly 49.4% overvalued today. We read business quality at 41/100 (below-average quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, CHLOGIST generated revenue of ₹715M at a net margin of -3.3%. Revenue declined 2.2% year over year. It earns a return on equity of -3.6%. Net debt stands at ₹146M. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹1.98 (bear case) to ₹3.32 (bull case); at ₹6.56, the current price sits above that range. The share trades about 35% below its 52-week high and 37% above its 52-week low, currently below its 200-day average.

Key figures & financial health

Revenue (TTM) ₹715M
Revenue growth (YoY) -2.2%
Net margin -3.3%
Return on equity -3.6%
Free cash flow ₹43.6M FY2026
Operating margin 0.6%
More key figures
EPS (TTM) ₹-0.1800
EPS growth (YoY) +15.4%
Net debt ₹146M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

CHLOGIST reported revenue of ₹715M in FY2026 versus ₹1.3B in FY2022, a compound −13.4%/yr. Reported net income was −₹23.2M in FY2026.

Revenue −13.4%/yr
FY22 ₹1.3B
FY23 ₹849M
FY24 ₹716M
FY25 ₹766M
FY26 ₹715M
Net income
FY22 ₹5.5M
FY23 ₹1.6M
FY24 ₹6.7M
FY25 ₹12.4M
FY26 −₹23.2M

Is CHLOGIST fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "CHLOGIST Fair Value". https://www.fairvalue-calculator.com/stock/CHLOGIST

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is CHLOGIST (CHLOGIST) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹3.32 versus a price of ₹6.56 — about −49% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CHLOGIST?
Our model-based fair value for CHLOGIST is ₹3.32 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹6.56.
What is the quality score of CHLOGIST?
CHLOGIST has a Quality Score of 41/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of CHLOGIST (CHLOGIST)?
CHLOGIST reported trailing-twelve-month revenue of about ₹715M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of CHLOGIST?
The net profit margin of CHLOGIST is about -3.3%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.